There is 1 paper on clinically symptomatic respiratory illness in aging research: 1 trial in people.
1 paper studies it2 findings
See all 1 papers on clinically symptomatic respiratory illness
- Human trial1
Interventions
1Dactolisib
no changein humans1OR 1
1 study
Dactolisib
no changein humans1OR 1
Dactolisib showed no clear effect on clinically symptomatic respiratory illness in humans (OR 1·07 [95% CI 0·80–1·42]).
“In the full analysis set, RTB101 did not reduce the proportion of patients with clinically symptomatic respiratory illness, the primary endpoint of the trial”
Human trial16 weeksn = 1,024
The lancet. Healthy longevity
Dactolisib showed no clear effect on clinically symptomatic respiratory illness in humans (phase 3 trial) (26% vs 25%; OR 1·07 (90% CI 0·80-1·42); p=0·65).
“RTB101 did not reduce the proportion of patients with clinically symptomatic respiratory illness”
Human trialphase 3 trial10 mg once daily16 weeksn = 1,024
The lancet. Healthy longevity
Latest
The Lancet Healthy Longevity
Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials
Randomized trial in 1,024 peoplemTOR inhibitors